Ecto-GPR37: a potential biomarker for Parkinson's disease

Area of Science:

• Neuroscience
• Biomarker Discovery

Background:

• Parkinson's disease (PD) lacks reliable biomarkers.
• α-Synuclein has shown inconclusive results as a PD biomarker.
• GPR37 is implicated in parkinsonism.

Purpose of the Study:

• Investigate GPR37 upregulation in sporadic PD.
• Assess GPR37 as a potential PD biomarker.

Main Methods:

• Analyzed GPR37 protein and mRNA in postmortem substantia nigra from PD patients.
• Detected and quantified N-terminus-cleaved GPR37 (ecto-GPR37) peptides in cerebrospinal fluid (CSF) using mass spectrometry and immunoassay.
• Compared CSF ecto-GPR37 levels in PD, neurological control, and Alzheimer's disease patients.

Main Results:

• GPR37 protein and mRNA were significantly increased in sporadic PD substantia nigra.
• CSF ecto-GPR37 peptides were elevated in PD patients.
• CSF α-synuclein levels did not differ between PD patients and controls.
• GPR37 expression and CSF ecto-GPR37 levels were unaltered in Alzheimer's disease patients.

Conclusions:

• GPR37 expression is elevated in the substantia nigra of sporadic PD patients.
• CSF ecto-GPR37 is significantly increased in PD patients but not AD patients.
• GPR37 warrants further investigation as a potential PD biomarker.